Kastle Therapeutics, LLC
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kastle Therapeutics, LLC
Novartis And The Medicines Company: Five Things To Worry About
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
Interview: OliPass An Oligonucleotide Outsider With Big Ambitions
South Korean bioventure OliPass tells Scrip how it intends to grab a leading position in the global antisense oligonucleotide drug sector using in-house developed technology that it says can both sharply lower prices and increase safety in the field, where it is initially focusing on novel pain therapies.
Ionis: Another Shot At The Commercial Market And Sustainable Profits
Spinraza, launched by partner Biogen, is the antisense developer’s newest drug to reach the market. Ionis plans to file its first wholly-owned drug, volanesorsen, later this year.
Deals Shaping The Medical Industry, June 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2016.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice